SIGMAR1 and schizophrenia: It is noteworthy that NE-100 pretreatment abrogated the cellular and behavioral effects afforded by fluvoxamine, confirming the role of Sig-1R in mediating fluvoxamine’s possible therapeutic effects in the current model of schizophrenia.